Document Detail

Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children.
MedLine Citation:
PMID:  18294107     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVES: To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise-induced bronchospasm in children with mild-to-moderate asthma, and to determine whether cysteinyl leukotriene (Cys-LT) concentrations measured in the exhaled breath condensate correlated with response to montelukast. DESIGN: Prospective, randomized, double-blind, double-dummy, crossover study. SETTING: Asthma clinic at a university-affiliated medical center. PATIENTS: Eleven children aged 7-17 years with physician-diagnosed mild-to-moderate asthma for at least 6 months and with self-reported exercise-induced bronchospasm (defined as > or = 15% decrease in forced expiratory volume in 1 sec [FEV(1)] at screening and baseline visit). INTERVENTION: Patients were randomly assigned to receive 3-7 days of oral montelukast 5-10 mg/day or 2 puffs of an albuterol metered-dose inhaler just before an exercise challenge and then were crossed over to the alternate therapy for the last visit. MEASUREMENTS AND MAIN RESULTS: Serial spirometry was performed before and at 0, 5, 10, 15, 30, 45, and 60 minutes after the exercise challenge at each visit. Measurement of exhaled breath condensate was performed at the screening visit and study visits 1 and 2. The primary outcome was the maximum change in FEV(1) after exercise. Secondary outcomes were the area under the curve for FEV(1) (expressed as percentage decrease from baseline) during the first 60 minutes (AUC(0-60)) after exercise and the proportion of patients in whom exercise-induced bronchospasm was prevented (defined as < 15% decrease in FEV(1) after exercise challenge). The mean +/- SD maximum decrease in FEV(1) was 27.5 +/- 7.9% at baseline. Patients receiving montelukast had an 18.3 +/- 13.7% decrease in FEV(1) compared with 0.7 +/- 1.6% in patients receiving albuterol (p=0.002, paired t test). Exercise-induced bronchospasm was prevented in 100% of the patients receiving albuterol compared with 55% receiving montelukast (p<0.05, McNemar's test). The AUC(0-60) was significantly smaller with albuterol compared with montelukast (p<0.001, Wilcoxon signed rank test). No correlations were found between Cys-LT concentration and the severity of exercise-induced bronchospasm or the response to montelukast. CONCLUSION: Pretreatment with albuterol is more effective than montelukast for prevention of exercise-induced bronchospasm in children with asthma.
Hengameh H Raissy; Michelle Harkins; Franceska Kelly; H William Kelly
Related Documents :
24330677 - The fat spondyloarthritis spine score (fasss): development and validation of a new scor...
14673897 - Paroxysmal exercise-induced dystonia as a presenting feature of young-onset parkinson's...
2856867 - Exercise-induced asthma.
18096677 - Improved naming after transcranial direct current stimulation in aphasia.
24354777 - Layering garments during rest and exercise in the cold (8°c): wearer responses and com...
10638947 - Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in b-...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacotherapy     Volume:  28     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-25     Completed Date:  2008-06-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  287-94     Citation Subset:  IM    
Departments of Pediatrics, School of Medicine, University of New Mexico, Albuquerque, New Mexico 87131-0001, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetates / therapeutic use*
Adrenergic beta-Agonists / therapeutic use*
Albuterol / therapeutic use*
Anti-Asthmatic Agents / therapeutic use*
Asthma, Exercise-Induced / prevention & control*
Cross-Over Studies
Double-Blind Method
Forced Expiratory Volume
Hospitals, University
Prospective Studies
Quinolines / therapeutic use*
Grant Support
5-M01-RR-00997/RR/NCRR NIH HHS
Reg. No./Substance:
0/Acetates; 0/Adrenergic beta-Agonists; 0/Anti-Asthmatic Agents; 0/Quinolines; 158966-92-8/montelukast; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
Next Document:  In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, agai...